Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Short-term Investments (2017 - 2026)

Corcept Therapeutics (CORT) has disclosed Short-term Investments for 10 consecutive years, with $229.4 million as the latest value for Q1 2026.

  • For Q1 2026, Short-term Investments fell 1.5% year-over-year to $229.4 million; the TTM value through Mar 2026 reached $229.4 million, down 1.5%, while the annual FY2025 figure was $251.7 million, 1.57% down from the prior year.
  • Short-term Investments hit $229.4 million in Q1 2026 for Corcept Therapeutics, down from $251.7 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $365.3 million in Q4 2022 and bottomed at $165.1 million in Q1 2023.
  • Average Short-term Investments over 5 years is $265.7 million, with a median of $251.7 million recorded in 2025.
  • Year-over-year, Short-term Investments skyrocketed 150.38% in 2022 and then crashed 42.98% in 2023.
  • Corcept Therapeutics' Short-term Investments stood at $365.3 million in 2022, then plummeted by 36.31% to $232.7 million in 2023, then increased by 9.88% to $255.7 million in 2024, then fell by 1.57% to $251.7 million in 2025, then dropped by 8.83% to $229.4 million in 2026.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $229.4 million, $251.7 million, and $296.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.